# CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Article · Haydar Frangoul, David Altshuler, Maria Domenica Cappellini, Yi-Shan Chen, Jennifer Domm, Brenda K. Eustace, Juergen L. Foell, Josu de la Fuente, Stephan A. Grupp, Rupert Handgretinger, Tony W. Ho, Antonis Kattamis, Andrew M. Kernytsky, Julie A. Lekstrom-Himes, Amanda M. Li, Franco Locatelli, Markus Y. Mapara, Mariane de Montalembert, Damiano Rondelli, Akshay Sharma, Sujit Sheth, Sandeep Soni, Martin H. Steinberg, Donna Ann Wall, Angela Yen and 1 more

- Archive id: doi:10.1056/nejmoa2031054
- Published: 2020-12-05
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa2031054
- PMID: 33283989
- Citations: 1,960
- Source URL: https://doi.org/10.1056/nejmoa2031054
- PDF: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031054?articleTools=true
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.